| NCT ID | NCT04645251 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Portsmouth Hospitals NHS Trust |
| Condition | Polycystic Liver Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2021-01-21 |
| Primary Completion | 2030-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2021-01-21 with a primary completion date of 2030-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Multicentre, observational registry studying the natural course of polycystic liver disease.
Eligibility Criteria
Inclusion Criteria: * Patients with PLD with more than 10 liver cysts * Patients with PKD and PLD with more than 10 liver cysts Exclusion Criteria: * Patients with PKD or PLD with less than 10 liver cysts
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04645251 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Polycystic Liver Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04645251 currently recruiting?
Yes, NCT04645251 is actively recruiting participants. Contact the research team at richard.aspinall@porthosp.nhs.uk for enrollment information.
Where is the NCT04645251 trial being conducted?
This trial is being conducted at Nijmegen, Netherlands, Portsmouth, United Kingdom.
Who is sponsoring the NCT04645251 clinical trial?
NCT04645251 is sponsored by Portsmouth Hospitals NHS Trust. The trial plans to enroll 500 participants.